

DAFTAR PUSTAKA

1. Koyama Y, Brenner D A. Liver Inflammation and Fibrosis. *The Journal of Clinical Investigation*. 2017; 127(1). <https://doi.org/10.1172/JCI88881>.
2. Zhangdi HJ et al. Crosstalk network among multiple inflammatory mediators in liver fibrosis. *World Journal Gastroenterology*. 2019; 25(33): 4835-4849.
3. Nusrat S, Khan M S, Fazili J, Madhoun M F. *Cirrhosis and Its Complications: Evidence Based Treatment*. Baishideng Publishing Group Co. 2014;20(18).
4. Ge P S, Runyon B A. Treatment of Patients with Cirrhosis. *N Engl J Med*. 2016; 375: 767-77. Doi: 10.1056/NEJMra1504367.
5. Asrani S K, Devarbhavi H, Eaton J, Kamath P S. Burden of liver diseases in the world. *Journal of Hepatology*. 2019; 70: 151–171.
6. Wong M C S, Huang J J. The Growing Burden of Liver Cirrhosis: Implication for preventif measure. *Hepatology International*. 2018;12:201-203.
7. Setiawan M. Hubungan Antara Kejadian Asites Pada Cirrhosis Hepatis Dengan Komplikasi Spontaneous Bacterial Peritonitis. *Bagian Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Muhammadiyah Malang* 2011;7(15).
8. Kalista K F, Lesmana C R A, Sulaiman A S, Gani R A, Hasan I. Profil Klinis Pasien Sirosis Hati dengan Varises Esofagus yang Menjalani Ligasi Varises Esofagus di Rumah Sakit Dr. Cipto Mangunkusumo. 2019;6(1).
9. Elfatma Y, Arnelis, Rachmawati N. Gambaran derajat varises esofagus berdasarkan beratnya sirosis hepatis. *Jurnal Kesehatan Andalas*. 2017;6(2).
10. Farida Y, Andayani T M, Ratnasari N. Analisis Penggunaan Obat Pada Komplikasi Sirosis Hati. *Jurnal Manajemen dan Pelayanan Farmasi*. 2014; 4(2).
11. Lovena A, Miro S, Efrida. Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2017; 6(1).
12. Klarisa C, Liwang F, Hasan I. Kapita Seleкта : Sirosis Hepatis. *Media Aesculapius*. 2014;Ed.4(2);693-697.

13. Zhou WC et al. Pathogenesis of liver cirrhosis. *World Journal of Gastrology*. 2014;20(23).
14. Geong G Y, Kang S H, Lee C M. An updated review on the epidemiology, pathophysiology, etiology, and diagnosis of liver cirrhosis. Seoul National University. 2019.
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *Journal of Hepatology*. 2018. <https://doi.org/10.1016/j.jhep.2018.03.024>.
16. Moller S, Henrikson J H, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. *World Journal of Gastroenterology*. 2014; 20(42): 15499-15517.
17. Wang et al. A correlation between gastrointestinal dysfunction and cirrhosis severity. *Medicine*. 2018;97:37.
18. Elmakki E. Hipersplenisme : Review Article. *Journal of Biology, Agriculture and Healthcare*. 2012; 2(10): 2224 – 3208.
19. Schuppan D, Afdhal N H. Liver Cirrhosis. *Lancet*. 2008;371(9615);838-851.
20. Carvalho JR, et al. New Insights About Albumin and Liver Disease. *Annals of Hepatology*. 2018;17(4): 547-560.
21. Bernardi et al. Human albumin in the management of complications of liver cirrhosis. *Critical Care*. 2012; 16: 211.
22. Walayat S et al. Role of Albumin in Cirrhosis: From A Hospitalist's Perspective. *Journal of Community Hospital Internal Medicine Perspectives*. 2017;7(1):8-14.
23. Lindsay et al. Paracentesis-Induced Circulatory Dysfunction: A Primer for the Interventional Radiologist. *Seminars in Interventional Radiology*. 2014;31(3).
24. Rena N M R A, Wibawa I D N. Albumin Infusion in Liver Cirrhotic Patients. *Acta Med Indones-Indones J Intern Med*. 2010;42(3).
25. Saqib W et al. Role of albumin in cirrhosis: from a hospitalist's perspective. *Journal OF Community Hospital Internal Medicine Perspectives*. 2017; 7(1): 8–14. <http://dx.doi.org/10.1080/20009666.2017.1302704>.

26. Myanmar Medical Association. Clinical Practice Guidelines for The Cirrhosis of Liver 2017. Myanmar Medical Association. 2017.
27. C. Aubé et al. Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. Elsevier. 2017; 98: 455—468.
28. Piano et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. *Clinical Gastroenterology and Hepatology*. 2018; 16: 1792–1800.
29. Gangopadhyay K K, Singh P. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. *Indian Journal of Endocrinology and Metabolism*. 2017; 21: 341-354.
30. Peng Y, Qi X, Guo X. *Child–Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis A Systematic Review and Meta-Analysis of Observational Studies*. *Medicine*. 2016. 95(8): e2877.
31. Tsois A, Marlar CA. Use Of The *Child Pugh Score In Liver Disease*. [Updated 2019 May 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542308/>.
32. Suva M A. A Brief Review on Liver Cirrhosis: Epidemiology, Etiology, Pathophysiology, Symptoms, Diagnosis and Its Management. *Inventi Rapid: Molecular Pharmacology*. 2014(2): 1-5.
33. Tungadi N W. Hubungan Nilai Prothrombin Time dan Albumin Dengan Staging Pasien Sirosis Hepatis di RSUP Dr. Wahidin Sudirohusodo Makassar Periode Januari – Desember 2016. Fakultas Kedokteran Universitas Hasanudin. 2017.
34. World Health Organization. Guidelines For The Prevention, Care And Treatment Of Persons With Chronic Hepatitis B Infection. World Health Organization. 2015.
35. Foucher, Chanteloup, Vergniol, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*. 2006;55:403–408. doi:10.1136/gut.2005.069153.

36. Rockey D C. Noninvasive Assessment of Liver Fibrosis and Portal Hypertension With Transient Elastography. *Gastroenterology*. 2008; 134: 8–14.
37. Tambunan A, Mulyadi Y, Kahtan M I. Characteristics Of Cirrhotic Patients In Dr. Soedarso General Hospital Pontianak Periods Of January 2008 – December 2010. 2010.
38. Mandrowinduro P, Hasan I, Alwi I, Abdullah M. Disfungsi Diastolik Ventrikel Kiri Pada Pasien Sirosis Haati: Proporsi, Korelasi, dan Hubungan Parameter Fungsi Diastolik Dengan Derajat Disfungsi Hati. *Jurnal Penyakit Dalam Indonesia*. 2018; 5(1).
39. Shashidhar KN and Krishna Sumanth Nallagangula. Pros and Cons of Existing Biomarkers for Cirrhosis of Liver. *Acta Scientific Medical Sciences* 3.6 (2019): 63-72.
40. J. Ozougwu. Physiology of The Liver. *International Journal of Research in Pharmacy and Biosciences*. 2017;4(8): 13-24
41. Rosida A. Pemeriksaan Laboratorium Penyakit Hati. *Berkala Kedokteran*. 2016; 12(1): 123-131.
42. Fitmawati, Titrawani, dan Safitri W. Struktur Histologi Hati Tikus Putih (*Rattus norvegicus* Berkenhout 1769) dengan Pemberian Ramuan Tradisional Masyarakat Melayu Lingga, Kepulauan Riau. *Ekotonia: Jurnal Penelitain Botani, Zoologi dan Mikrobiologi*. 2018; 04(1): 11-19.
43. Junaidi A, Ramadhania Z M. Potensi Silymarin (Hepamax) Sebagai Suplemen dan Terapi Penunjang Pada Gangguan Liver. *Farmaka*. 2018;16(1).
44. Shipley L C, Axley P D, Singal A K. Liver Fibrosis: A Clinical Update Authors. *Europeans medical journal Hepatology*. 2019; 7(1): 105-117.
45. Wasim M et al. Assessment of Risk Factors and Clinical Presentations in a Liver Cirrhotic State-Pakistan. *World Applied Sciences Journal*. 2014; 32 (7): 1252-1257.
46. Kaplan D E et al. Recalibrating the *Child–Turcotte–Pugh* Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. *Dig Dis Sci*. 2016; 61: 3309–3320. DOI 10.1007/s10620-016-4239-6..

47. I.I. Elmahalawy et al. Respiratory and cardiovascular complications in patients with liver cirrhosis due to hepatitis C virus and its impact on quality of life. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2017; 66: 157–163.
48. Ivanova I. Liver Cirrhosis: New Concepts. *Scripta Scientifica Medica*. 2016; 48(2): 9-16.
49. Ohkoshi S, Hirona H, Watanabe K, Hasegawa K, kamimura K, Yano M. Natural Regression of Fibrosis in Chronic Hepatitis B. *World Journal of Gastroenterology*. 2016; 22(24): 5459-5466.
50. Tang L S Y, Covert E, Wilson E, Kotilil S. Chronic Hepatitis B Infection A Review. *JAMA*. 2018;319(17).
51. Bataller R, Brenner D A. Liver Fibrosis. *J Clin Invest*. 2005;115(2):209-218. <https://doi.org/10.1172/JCI24282>.
52. Safithri F. Mekanisme Regenerasi Hati secara Endogen pada Fibrosis Hati. *Fakultas Kedokteran Universitas Muhammadiyah Malang*. 2018; 2(4).
53. George J, Tsuchishima M, Tsusumi M. Molecular Mechanisms in The Pathogenesis of N-nitrosodimethylamine Induced Hepatic Fibrosis. *Official Journal of The Cell Death Differentiation Association*. 2019; 10: 18.
54. Ebrahimi H, Naderian M, Sohrabpour A A. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. *Middle East Journal of Digestive Diseases*. 2016;8(3).
55. Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. *Journal of Hepatology*. 2019; 70: 294-304.
56. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. *International Journal of Molecular Science*. 2019; 20: 1358.
57. Nallagangula K S, Pradhan R, N S K. Molecular and Epigenetic Mechanisms of Bidirectional Liver Fibrosis. *American Journal of Liver and Clinical Research*. 2017;1(1):001-006.
58. Schaefer E A, Friedman L S. Overview: Clinical Fundamentals of Hepatology. *John Wiley & Sons Ltd*. 2018. Ed 12.

59. Kang J S, Min H L, Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with Chronic Liver Disease. Department of Pharmacology College of Medicine Hanyang University. 2017.
60. Sauerbruch T, Wong F. Treatment of Oesophageal Varices in Liver Cirrhosis. *Digestion*. 2019; 99: 261–266. DOI: 10.1159/000492076.
61. Sood R. Ascites : Diagnosis and Management. *Journal of Indian Academy of Clinical Medicine*. 2003; 5(1).
62. Pinto R B et al. Cirrhosis in Children and adolescents: An overview. *World Journal of Hepatology*. 2015; 7(3).
63. Francoz et al. Hepatorenal Syndrome. *Clinical Journal of the American Society of Nephrology*. 2019; 14.
64. Pinter M, Trauner M, Peck-Radosavljevic M, et al. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open* 2016;1:e000042. doi:10.1136/esmoopen-2016- 000042
65. Belousov A. Albumin and its Application. *Mathews Journal of Case Reports*. 2019;4(1).
66. Akirov et al. Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. *The American Journal of Medicine*. 2017;130(12).
67. Levitt D G, Levitt M D. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *International Journal of General Medicine*. 2016; 9.
68. Perinandika T, S R D, Dwiyaningrum F. A Study of Hypoalbuminemia and Pleural Effusion in Pediatric Nephrotic Syndrome. *AMJ*. 2017;4(2):188–91.
69. Gomi I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K, Moriwaki H. Relationship Between Serum Albumin Level and Aging in Community-Dwelling Self-Supported Elderly Population. *J Nutr Sci Vitaminol*. 2007; 53: 37-42.

70. Sitompul E, Sorimuda S, Jemadi J. Karakteristik Penderita Sirosis Hati yang dirawat Inap di Rumah Sakit Santa Elizabeth Medan. *Jurnal Universitas Sumatera Utara*. 2014.
71. Yulianda D, Maharani L, Suryoputri M W. Penggunaan Albumin Oral dan Albumin Injeksi pada Pasien Sirosis Hati di RSUD Prof. Dr. Margono Soekarjo Purwokerto. *Acta Pharm Indo*. 2020; 8(1): 8-15.
72. Marselina N M T. Gambaran Klinis Pasien Sirosis Hati: Studi Kasus Di RSUD Dr Kariadi Semarang Periode 2010-2012. *Jurnal Media Medika Muda*. 2014.
73. Patasik Y Z, Walelang B J, Wantania F. Profil Pasien Sirosis Hati yang Dirawat Inap di RSUD PROF. Dr. R. D. Kandou Manado Periode agustus 2012 – agustus 2014. *Jurnal e-Clinic (eCI)*. 2015; 3(1).
74. Poluan P M, Kawengian V, Sugeng C. Hubungan Derajat Keparahan Sirosis Hepatis dan Nilai Laju Glomerulus pada Sirosis Hati. *Jurnal e-Clinic (eCI)*. 2015; 3(1).
75. Maharani S, Efendi D, Tampubolon L A. Gambaran Pemeriksaan Fungsi Hati pada Pasien Sirosis Hepatis di Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau tahun 2013 – 2015. *JIK*. 2018;12(1): 46 – 51.
76. Islam Md N et al. Plasma Prothrombin Time and Esophageal Varices in Patient with Cirrhosis of Liver. *Euroasian Journal of Hepato Gastroenterology*. 2016; 6(1): 10 – 12.
77. Fauziah N N. Hubungan Kadar Albumin Dengan Ultrasonografi pada Asites Minimal dan Asites Masif Penderita Sirosis Hati di Rumah Sakit Dustira. *Fakultas Kedokteran Unjani Cimahi*. 2017.
78. Suyosa S, Mustika S, Achmad H. Ensefalopati hepatic pada Sirosis Hati: Faktor Presipitasi dan Luaran Perawatan di RSUD dr. Syaiful Anwar Malang. *Jurnal Kedokteran Brawijaya*. 2015; 28(4).
79. Koncoro H et al. Kadar Resistin Serum Berhubungan dengan Skor Child Turcotte Pugh pada Penderita Sirosis hati. *Jurnal Penyakit Dalam Udayana*. 2017; 1(1).

80. Agarwal et al. Correlation of Trace Elements in Patient of Chronic Liver Disease With Respect to Child Turcotte Pugh Scoring System. *Journal of Clinical and Diagnostic Research*. 2017; 11(9): OC25 – OC26.

